

Supplementary Table 2 Second MRI assessment of tumour burden in *Tsc1*^{+/-} mice after treatment

(Mann Whitney test)

A. Lesion number (all cystic, papillary and solid lesions)

Treatment*	Number of mice	Median	Range	P (compared with Vehicle)	P (compared with Rapamycin)	P (compared with Rapamycin+Atorvastatin)
Vehicle	6	17	14-36			
Atorvastatin	6	21	19-40	0.1623	0.0022	0.0022
Rapamycin	6	14.5	4-17	0.1797		
Rapamycin+Atorvastatin	6	12.5	8-17	0.0173	0.7792	

B. Lesion volume (all cystic, papillary and solid lesions)

Treatment*	Number of mice	Median (mm ³)	Range (mm ³)	P (compared with Vehicle)	P (compared with Rapamycin)	P (compared with Rapamycin+Atorvastatin)
Vehicle	6	46.08	20.66-158.82			
Atorvastatin	6	45.975	21.98-119.98	0.9372	0.0087	0.0022
Rapamycin	6	9.695	2.36-36.99	0.0087		
Rapamycin+Atorvastatin	6	6.62	2.32-20.5	0.0022	0.4848	

* The 2nd MRI scan was performed after two months' treatment at the age of 14 months.